Donanemab, an Alzheimer’s drug, received unanimous backing from FDA advisors for its ability to slow cognitive decline, marking a positive step in Alzheimer’s treatment. Despite modest benefits and concerns about its long-term effectiveness, the approval signifies progress in Alzheimer’s therapeutics.

To read the full article, click here: Alzheimer’s drug with modest benefits wins backing of FDA advisers (nature.com)